IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
-
-
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced data evaluating LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19…
-
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
-
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
-
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the U.S. Food and Drug Administration (FDA) had given clearance to…
-
Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
-
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
-
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
US Food and Drug Administration revised EUA for sotrovimab due to Omicron BA.2 subvariant
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration (FDA) had…
-
Quest Diagnostics granted CDC contract to support COVID-19 infection and vaccination seroprevalence research
On Mar. 23, 2022, Quest Diagnostics announced that it had been granted a contract by the Centers for…
-
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
-
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
-
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
-
Windtree announced results from phase 2 study of lucinactant for COVID-19 associated ARDS and Lung Injury
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
-
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
-
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
-
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
-
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax™ (heat stable COVID-19…
-
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
-
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
-
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
-
COVID-19 | HIV | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
-
CDC reported effectiveness of 2-Dose BNT162b2 mRNA vaccine in preventing SARS-CoV-2 infection among children
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by the Centers for Disease Control and…
-
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
-
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, a COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to…
-
Oragenics engages KBI Biopharma to support development of intranasal COVID-19 vaccine candidate NT-CoV2-1
On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the…
-
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
-
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
-
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
-
University of Oxford reported brain regions related to smell show decline following mild COVID-19
On Mar. 7, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
